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Abstract
Pelizaeus-Merzbacher disease (PMD) is a rare X-linked dys-
myelination disorder of the central nervous system (CNS).
PMD is caused by mutations in the PLP1 gene located at
Xq22 and encoding the major myelin component in CNS,
proteolipid protein 1 (PLP1). The disease is clinically hete-
rogeneous. Phenotypes are generally categorized into classic
and connatal forms. Connatal PMD has more rapid pro-
gression with early death, while patients with classic PMD
generally survive to adulthood. Both forms of the disease are
caused by point mutations as well as rearrangements – mul-
tiplication (mainly duplication) and deletion of the PLP1
gene.
We present a case of a male patient affected by the classic form
of PMD with benign course, except severe dysarthria with
the characteristic laryngeal stridor, which is more typical for
connatal form of the disease. The diagnosis has been confir-
med at the molecular level. The patient has duplication of all
7 exons of the PLP1 gene. This duplication was inherited
from the patient’s mother, who is an unaffected carrier of the
mutation. The patient’s family pedigree analysis revealed the
PLP1 gene duplication as a cause of the classic form of Pelizaeus-Merzbacher
disease – case report
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CASE REPORT/OPIS PRZYPADKU
St reszc zen ie  
Choroba Pelizaeusa-Merzbachera (Pelizaeus-Merzbacher dise-
ase – PMD) to rzadka, sprzê¿ona z chromosomem X cho-
roba dysmielinizacyjna oœrodkowego uk³adu nerwowego
(OUN). Spowodowana jest mutacjami znajduj¹cego siê
w locus Xq22 genu PLP1, koduj¹cego g³ówny sk³adnik
otoczki mielinowej OUN, bia³ko proteolipidowe 1 (PLP1).
Charakteryzuje siê heterogennoœci¹ obrazu klinicznego.
Wyró¿niamy dwie jej postacie – wrodzon¹ i klasyczn¹. W obu
formach pierwsze objawy wystêpuj¹ ju¿ we wczesnym dzie-
ciñstwie. W postaci wrodzonej progresja choroby jest jednak
zdecydowanie szybsza, w postaci klasycznej pacjenci osi¹gaj¹
zazwyczaj œredni wiek ¿ycia. Pod³o¿e molekularne obu po -
staci choroby stanowi¹ zarówno mutacje punktowe, jak
i rearan¿acje genu – multiplikacje (g³ównie duplikacje) oraz
delecje genu PLP1.
W pracy przedstawiono opis przypadku mê¿czyzny z kla-
syczn¹ postaci¹ PMD o ³agodnym przebiegu, u którego
wystêpowa³y objawy charakterystyczne dla postaci wrodzo-
nej – nasilone zaburzenia artykulacji mowy o typie stridoru
krtaniowego. Rozpoznanie choroby zosta³o potwierdzone
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Introduction
Pelizaeus-Merzbacher disease (PMD; OMIM
312080) is a rare X-linked recessive leukodystrophy [1].
It is an allelic form of spastic paraplegia type 2 (SPG2;
OMIM 312920) [1]. Both disorders are caused by
mutations of the PLP1 gene (OMIM 300401), located
at locus Xq22 and coding proteolipid protein 1 (PLP1)
– the main component of myelin in the central nervous
system (CNS) [1,2]. PLP1-related disorders represent
a spectrum of the CNS white matter diseases caused by
the gene dosage effect and point mutations of the gene.
Increased dosage of the PLP1 protein is the major cau-
se of PMD. About 60-70% of patients have a submi-
croscopic duplication on chromosome X, including the
entire PLP1 gene. In rare cases, patients having three
or even five PLP1 copies have been described [2,3].
Point mutations in the PLP1 gene are found in 15-20%
of cases [2,3]. A few known patients have deletion or
null mutation of the PLP1 gene which result in protein
loss [4]. As an X-linked recessive disorder, PMD
affects hemizygous males, while female carriers are gene-
rally asymptomatic. They can show, however, some neu-
rological symptoms, especially if they carry PLP1 point
mutations [5].
PLP1-related phenotypes show considerable varia-
tion, but the common features include nystagmus, stri-
dor, ataxia, psychomotor developmental delay and spa-
sticity. The onset of disease is usually in the first year of
life. Disease severity ranges from the most severe, con-
natal PMD through the classic form to mild PMD and
SPG2. The molecular background of such phenotypic
variability is not completely understood but there is some
general association between the disease severity and 
the type of causative mutation [6]. Connatal form is
mainly associated with missense mutations in the most
 conserved PLP1 regions. Gene duplications are most
often found in patients with classic form of the disease.
The less severe forms of the disease result from loss of
the PLP1 gene products [4]. Intrafamilial variability in
the disease course suggests the influence of additional
modifier genes on the final phenotype [7].
PMD is divided into classic and connatal types.
Although these two types differ in severity, their featu-
res can overlap. The connatal form is the most severe
form of the disease. It appears from birth and involves
delayed mental and physical development and severe
neurological symptoms. Affected boys usually die at an
early age due to quick progression of the illness. In rare
cases they can live until the third decade of life but are
completely speechless [2,8]. The classic form has slo-
wer progress of symptoms including muscle weakness,
nystagmus and delayed motor development in the first
year of life followed by ataxia, movement disorders of
the trunk and upper limbs characteristic for dystonia,
and sometimes athetosis and choreatic movements. Pyra-
midal symptoms with spastic paraparesis appear and
develop slowly. Boys are able to articulate single words
and most of them start to walk independently. In adole-
scence, a regression in patients’ development and wal-
king skills can be observed. They often achieve an ave-
rage level of intellectual development. Patients suffering
from classic PMD can usually survive to the third,
fourth or even seventh decade of life [2]. 
In this report we present a case of a patient with clas-
sical form of PMD, confirmed by genetic analysis and
caused by the duplication of all exons of the PLP1 gene,
inherited from his mother, an asymptomatic carrier of
this mutation on one X chromosome.
Case report
A 20-year-old man was admitted to the Department
of Neurology in Bródno Hospital. According to his
mother, the first symptoms of his illness appeared just
interfamilial variability of the phenotype among affected male
relatives.
Key words: Pelizaeus-Merzbacher disease, dysmye lination
disorder, leukodystrophy, PLP1, gene duplication, MLPA.
badaniami genetycznymi. U pacjenta stwierdzono duplika-
cjê wszystkich eksonów genu PLP1. Mutacja zosta³a odzie-
dziczona od matki, bezobjawowej nosicielki. Analiza rodo-
wodowa wykazuje u chorego rodzinn¹ postaæ choroby
o zmiennym obrazie fenotypowym u spokrewnionych cho-
rych p³ci mêskiej. 
S³owa kluczowe: choroba Pelizaeusa-Merzbachera, choroba
dysmielinizacyjna, leukodystrofia, PLP1, duplikacja genu,
MLPA. 
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before his first birthday. They included head tremor at
rest, nystagmus and truncal ataxia, which at first made
him unable to sit, then to stand unsupported. The symp-
toms were followed by ataxia of limbs, and speech arti-
culation disorder. At that time, the diagnosis of cerebral
palsy was made. When he was 10 years old, weakness
of the lower limbs was noticed and head tremor at rest
became more intensive. Despite these symptoms the
patient was able to walk with help. 
Magnetic resonance imaging (MRI) at the age of
13 showed incomplete white matter myelination in the
brain with a band-like, tiger-striped image of white mat-
ter with areas of highly myelinated white matter located
around blood vessels surrounded by spheres of lower
myelination. Magnetic resonance spectroscopy (MRS)
revealed decreased choline/creatine ratio (with a stable
level of creatine) and reduced NAA/tCr in the regions
of dysmyelination. Visual evoked potentials showed
abnormally delayed latency of the Pmax. Other tests reve-
aled normal cerebrospinal fluid, lack of oligoclonal pro-
tein and protein IgG antibodies and normal level of cop-
per, ceruloplasmin, protein, albumin, immunoglobulin
and very long chain fatty acids (VLCFA) measured in
serum. Peripheral motor and sensory nerves’ conduc-
tion velocity was normal.
Neurological examination at the present admission
demonstrated mild nystagmus with the fast phase
towards the right, laryngeal stridor, muscle weakness
and decreased muscle tone in upper limbs, hyperexten-
sion of elbow joints, kinetic tremor of head and upper
limbs, truncal and upper limb ataxia, dystonia of neck,
trunk and upper limbs, spastic paraparesis of lower limbs
with joint contractures of ankles and knees, increased
deep tendon reflexes, bilateral Babinski sign and foot
clonus. Symptoms of dystonia had typical features of
action dystonia and were absent in the lying position.
Brain MRI revealed that the myelination process had
stopped at the child level (Fig. 1).
Psychological examination confirmed average level
of intellectual development – 99 points according to
WAIS-R.
As the clinical picture and the family data showing
X-linked inheritance of the disorder (Fig. 2) suggested
the diagnosis of PMD, molecular analysis of the PLP1
gene was performed. PLP1 copy number was determi-
ned by multiple ligation-dependent probe amplification
(MLPA) reaction using the commercially available test
reagent set SALSA P022 (MRC-Holland) containing
probes covering all PLP1 exons as well as control 
probes for autosomal, chromosome X and Y regions
(www.mrc-holland.com). The Ethical Committee of the
Institute of Mother and Child approved the genetic 
study. The DNA test was performed for the patient and
his mother, from whom informed consent was obtained.
In the case of the patient, analysis revealed whole gene
duplication (Fig. 3). The patient’s mother, who accor-
ding to pedigree data was suspected of being a mutation
carrier, was confirmed as an asymptomatic PLP1 gene
duplication carrier.
Fig. 1. Magnetic resonance images of the proband showing a typical picture
of leukodystrophy: hyperintense areas located in subcortical white matter 
of frontal lobes (A) and band-like hyperintensity in subcortical white matter
in the region of both insulas (B)
A
B
Neurologia i Neurochirurgia Polska 2010; 44, 5514
Discussion 
PMD is a rare disorder of unknown prevalence in
Poland. Data for the United States population indicate
a prevalence of 1 per 200 000-500 000 [2]. PMD acco-
unts for 6.5% of all leukodystrophies in Germany [9].
Most PMD patients have mutations in the PLP1 gene,
but there is a group of 5-10% of patients with no detect -
able defect in this gene. They may have mutations in
PLP1 remote from routinely examined regions (deep in
introns or the promoter region) or develop Pelizaeus-
Merzbacher-like disease 1 (PMLD1, OMIM 608804),
caused by mutations affecting the GJA12 gene (OMIM
608803). The disorder is virtually identical to PMD but
of a different type of inheritance – autosomal recessive.
The variability of the clinical picture of the disease may
cause additional problems with correct diagnosis. Indi-
viduals with PMD/SP2 are often initially diagnosed
with cerebral palsy or static encephalopathy. All these
diagnostic problems may cause that PMD may be more
prevalent than is recognized.
Analysis of the patient’s family pedigree suggested
the familial form of the disease with the patient’s mother
being an obligatory carrier of the mutation. PMD dia-
gnosis was confirmed at the molecular level. The patient
has duplication of all exons of the PLP1 gene and his
mother is a mutation carrier. Three male members of
the family also suffered from the disease. Based on ava-
il able data, we can classify their illness as connatal and
classic form of PMD. Our patient probably has the mil-
dest form of the disease, but because of the lack of full
clinical data from other affected members of the family,
a detailed comparison is not possible. 
From the clinical point of view, our patient showed
the typical classic form of PMD, with slow progression
and average intellectual development. The only devia-
tion from the classic form was the progressive dysarth-
ria with laryngeal stridor, which allowed him to speak
using only simple words, slowly and with much effort.
This severe disorder of speech articulation is more cha-
racteristic for the connatal form than for the mild form
of PMD [2,8]. 
Analysis of the patient’s history shows that in the case
of such a rare disease as PMD, additionally characteri-
zed by a heterogeneous clinical picture, genetic mole-
cular tests are necessary to establish the final diagnosis.
Confirmation of presence of the causative mutation is
also very important for the whole family, making it possi-
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Fig. 2. The pedigree of the proband’s family (CP, IV-2). Pelizaeus-Merzbacher disease is presented in the family in three generations showing the intrafamilial clinical
picture variability (CL PMD III-9, IV-2; CN PMD II-4, III-2). Molecular diagnosis was performed only for the proband and his mother.
Other females who are obligatory carriers are marked on the basis of pedigree analysis
male, female
female (obligatory carrier)
male affected with PMD (CL – classical form, CN – connatal form)
dead (a.d. – age of death)
dead (without PMD)
proband
I.1 I.2
II.1
III.1 III.2 III.3 III.4 III.5 III.6 III.7
IV.1 IV.2
CL PMD
20 y
CL PMD
a.d. 33 y
CN PMD
a.d. 4 y
II.2 II.3 II.4
CN PMD
a.d. 12 y
III.11III.10III.9III.8
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Fig. 3. Graphical results of detection of the PLP1 exons 1-7 duplication for our patient. Samples containing 100 ng of DNA were analysed by using MLPA P022 probe mix. 
(A) Peak profile of the MLPA analysis for proband C.P. (black) compared to control profile (grey). The difference in PLP1 exons 1-7 peak heights (indicated by arrows)
indicates the copy number change – duplication in proband’s gene. Data are summarized in dosage histogram (Ex1-7 – exon probes, C – control probes).
(B) Normalization MLPA ratio plot for proband PMD-CP and analysed controls PMD-K+M (non-PMD male), PMD-K+F (female), PMD-K-, no DNA control. Analysis
was performed by using the population normalization method. Exonic duplication is apparent from the presence of the outlying data points for PLP1 probes ‘above’
the threshold line (> 1.25) on the proband’s plot. On the female control plot the PLP1 and chromosome X derived probes are also located in this area
ble to test the potential carriers of the gene, and provi-
de the proper genetic counselling.
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